Literature DB >> 731414

Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat.

B E Dahlström, L K Paalzow.   

Abstract

Morphine was administered to rats by oral, intraportal, and intravenous routes in a dose of 7.6 mg . kg-1. From the serum concentration data after intraportal administration it was calculated that the first-pass elimination of morphine in the liver amounts to 72 +/- 2% (SD). The first-pass fraction eliminated after oral administration was 85 +/- 7% (SD), thus yielding a contribution by the gut mucosa of 46% to the overall first-pass elimination after an oral dose. The results were obtained with a general compartmental model which included the kinetics of enterohepatic recirculation. The oral availability was also estimated with the aid of pharmacological effect data. This availability was in good agreement with the corresponding value determined from the serum concentration data. The results suggest that morphine is subjected to enterohepatic recirculation and that the slowest phase of decline of morphine concentrations in serum might be due to this physiological process.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 731414     DOI: 10.1007/bf01062106

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  23 in total

1.  Biopharmaceutic influences on the anticholinergic effects of propantheline.

Authors:  M Gibaldi; B Grundhofer
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Distribution and excretion of radioactivity after administration of morphine-N-methyl C14 to rats.

Authors:  C H MARCH; H W ELLIOTT
Journal:  Proc Soc Exp Biol Med       Date:  1954-07

3.  Quantitative determination of morphine in biological samples by gas-liquid chromatography and electron-capture detection.

Authors:  B Dahlström; L Paalzow
Journal:  J Pharm Pharmacol       Date:  1975-03       Impact factor: 3.765

4.  Metabolism of morphine in the perfused rat liver.

Authors:  B E Dahlström; J Jonsson; L K Paalzow
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976-07

5.  Effects of alteration of hepatic microsomal enzyme activity on liver blood flow in the rat.

Authors:  A S Nies; G R Wilkinson; B D Rush; J R Strother; D G McDevitt
Journal:  Biochem Pharmacol       Date:  1976-09-01       Impact factor: 5.858

6.  Drug-absorption analysis from pharmacological data. I. Method and confirmation exemplified for the mydriatic drug tropicamide.

Authors:  V F Smolen; R D Schoenwald
Journal:  J Pharm Sci       Date:  1971-01       Impact factor: 3.534

7.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.

Authors:  J G Wagner
Journal:  J Theor Biol       Date:  1968-08       Impact factor: 2.691

8.  Pharmacological response data for comparative bioavailability studies of chlorpromazine oral dosage forms in humans: I. Pupilometry.

Authors:  V F Smolen; H R Murdock; W P Stoltman; J W Clevenger; L W Combs; E J Williams
Journal:  J Clin Pharmacol       Date:  1975 Nov-Dec       Impact factor: 3.126

9.  Morphine metabolism. II. Studies on morphine glucuronyltransferase activity in intestinal microsomes of rats.

Authors:  E Del Villar; E Sanchez; T R Tephly
Journal:  Drug Metab Dispos       Date:  1974 Jul-Aug       Impact factor: 3.922

10.  Studies of the enterohepatic circulation of morphine in the rat.

Authors:  C T Walsh; R R Levine
Journal:  J Pharmacol Exp Ther       Date:  1975-11       Impact factor: 4.030

View more
  30 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

3.  An experimental design strategy for quantitating complex pharmacokinetic models: enterohepatic circulation with time-varying gallbladder emptying as an example.

Authors:  Y M Wang; R H Reuning
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

4.  Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients--a comparison of two oral formulations.

Authors:  J Hasselström; N Alexander; C Bringel; J O Svensson; J Säwe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Enterohepatic circulation of opioid drugs. Is it clinically relevant in the treatment of cancer patients?

Authors:  G W Hanks; P J Wand
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

6.  In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide.

Authors:  Satish Sharan; Otito F Iwuchukwu; Daniel J Canney; Cheryl L Zimmerman; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2012-07-17       Impact factor: 3.922

7.  Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.

Authors:  J Hasselström; J Säwe
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

8.  Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons.

Authors:  J G Lloyd-Jones; P Robinson; R Henson; S R Biggs; T Taylor
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

9.  Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.

Authors:  J J Gullo; C L Litterst; P J Maguire; B I Sikic; D F Hoth; P V Woolley
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

10.  Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.